progress BUSINESS & INDUSTRY PART 3: C
Submitted photo
As part of its recently completed fi ve-year, $100 million investment plan, Cambrex completed the construction of a new, state-of-the-art quality con- trol building on its Charles City campus, as well as new administrative space and entry.
Cambrex expands operations, adds jobs in Charles City while growing globally
For The Press Cambrex has completed a fi ve-year, $100 million investment project that includes what the company says is a cutting edge quality control building in Charles City, part of a broader effort to modernize its phar- maceutical manufacturing operations and increase capacity worldwide. The expansion brought about 40 new jobs to the Charles City campus. “The completed investment in Charles City is a testament to our dedication to ex- cellence and innovation,” said Joe Nettle- ton, general manager in Charles City and vice president of operations. “We are proud to invest in our local communities, create new opportunities and bring state-of-the-art capabilities to our sites,” Nettleton said. The Charles City facility improvements not only modernize its infrastructure, but also re fl ects Cambrex’s commitment to maintaining the highest standards in pharma- ceutical manufacturing, the company said. In addition to the new quality control buildout, the multi-phase project includ- ed renovations to existing laboratories and administrative spaces, ensuring that the site remains at the forefront of the industry. Cambrex is a contract development and manufacturing organization (CDMO) that develops and produces active pharmaceu- tical ingredients, or APIs. Its Charles City facility is one of several the company oper- ates in North America and Europe. As part of its expansion, Cambrex added more than 150,000 square feet of capacity across multiple sites. In Karlskoga, Sweden, the company added two new 6-cubic-meter production lines, increasing its large-scale API manufacturing capacity by 50%. In High Point, North Carolina, a $40 mil-
Press photo by Bob Steenson
Cambrex Charles City fi nished its new front entry in the past year, along with completing other expansion build-out.
lion project doubled that facility’s capacity and added new laboratories and manufac- turing areas. The work in High Point is expected to bene fi t the Charles City operation, which typically takes on projects as they scale up. CAMBREX HAS ALSO REPORTED PROGRESS on sustainability goals, including a 20% reduction in greenhouse gas emissions com- panywide. The Charles City site earned a Silver EcoVadis rating, placing it in the top 15% of companies evaluated. In product development, Cambrex an- nounced its new liquid-phase peptide syn- thesis (LPPS) technology, a development and manufacturing method that the compa- ny said will revolutionize the production of therapeutic peptides. “This innovation allows for greater ef fi - ciency and scalability while reducing waste,
offering a more sustainable and cost-effec- tive manufacturing solution,” the company said. By enhancing peptide synthesis capabili- ties, Cambrex is positioned to meet the ris- ing global demand for these complex thera- peutic modalities, further solidifying its role as a leader in pharmaceutical manufacturing. Cambrex’s Q1 Scienti fi c division has also been expanding its stability storage ser- vices, with new facilities opening in Liège, Belgium, and Durham, North Carolina, in addition to its fl agship facility in Waterford, Ireland. These modern facilities provide tempera- ture-controlled environments for long-term and accelerated stability storage, supporting pharmaceutical companies in Europe and North America. Cambrex’s Q1 Scienti fi c division has ex- panded its pharmaceutical stability storage
services with new facilities in Belgium and North Carolina, in addition to its original site in Ireland. “Cambrex’s success is rooted in the suc- cess of the communities where we operate,” said Elena Bejan, head of API development and manufacturing in Charles City. “We look forward to continuing this journey to- gether.” With more than 40 years of experience and a team of 2,000 experts servicing glob- al clients from North America and Europe, Cambrex offers a range of specialized drug substance technologies and capabili- ties, including continuous fl ow, controlled substances, liquid-phase peptide synthesis, solid-state science, material characterization and highly potent APIs, the company said. For more information or to view job openings in Charles City, visit www.cam- brex.com.
F C 1
2
3
TUESDAY, MARCH 25, 2025 SPORTS & EDUCATION
TODAY BUSINESS & INDUSTRY
FRIDAY, MARCH 21, 2025 COMMUNITY
Made with FlippingBook Ebook Creator